FX-8474

FX-8474 is a small-molecule dual inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinases 1A (DYRK1A) and 1B (DYRK1B), currently in preclinical development by Felicitex Therapeutics for the treatment of Type 1 Diabetes. The compound belongs to the substituted 7-azaindole/quinoline chemical class and is designed to promote pancreatic β-cell proliferation and improve glucose homeostasis. In streptozotocin-induced diabetic mouse models, oral administration of FX-8474 demonstrated significant improvements in fasted glucose levels and glucose tolerance. The drug is characterized by its selectivity for DYRK1A/B with minimal activity against GSK3B, which helps mitigate potential off-target toxicity associated with other kinase inhibitors.